Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Mechanisms and Clinical Implications of Thrombosis in Paroxysmal Nocturnal Hemoglobinuria

    ... the risk, but does not completely prevent thrombosis. Eculizumab , a monoclonal antibody to complement factor C5, ... intravascular hemolysis and also thrombotic risk. As such, eculizumab treatment has dramatically improved the prognosis of PNH. The ...

    Research Article last updated 11/21/2011 - 3:08pm.

  2. Patrizia Ricci, PhD

    ... . Recently, the availability of the complement inhibitor eculizumab has dramatically improved the treatment of PNH. Nevertheless, about half of the patients treated with eculizumab shows a persistence of clinical signs of the disease. We have ...

    Grant Recipient last updated 09/14/2016 - 2:42pm.

  3. Paroxysmal Nocturnal Hemoglobinuria: A Complement-Mediated Hemolytic Anemia

    ... CD55 and CD59, on PNH cells. Complement inhibition by eculizumab leads to dramatic clinical improvement. While this therapeutic ...

    Research Article last updated 06/23/2015 - 9:32am.

  4. Paroxysmal nocturnal hemoglobinuria

    ... congenital anomalies-hypotonia-seizures syndrome 2. Eculizumab , first-in-class monoclonal antibody that inhibits ... should be reserved for patients with suboptimal response to eculizumab. Bone Marrow Diseases:  ...

    Research Article last updated 10/02/2014 - 8:35am.

  5. Chao-Yie Yang, MD, PhD

    ... . Current FDA-approved only treatment for PNH is eculizumab which is expensive, unable to eradicate PNH clone , not ... in PNH. Current only FDA-approved treatment for PNH is eculizumab which is expensive, unable to eradicate PNH clone , not ...

    Grant Recipient last updated 08/09/2016 - 1:02pm.

  6. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review

    ... been dramatically revolutionized by the development of eculizumab , which brings benefits in terms of hemolysis, quality of life, ...

    Research Article last updated 04/07/2015 - 12:36pm.

  7. Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry

    ... to evaluating the long-term safety and effectiveness of eculizumab in a global population, the registry aims to improve diagnosis, ... anticoagulation (31%), immunosuppression (19%), and eculizumab (25%). Frequently reported symptoms included fatigue (80%), dyspnea ...

    Research Article last updated 03/06/2014 - 11:30am.

  8. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition

    ... mortality, or treatment with the complement inhibitor eculizumab . Eculizumab is a first-in-class anti-complement drug that in PNH has been shown ...

    Research Article last updated 11/05/2013 - 12:37pm.

  9. How I treat paroxysmal nocturnal hemoglobinuria.

    ... transplantation is the only curative therapy for PNH. Eculizumab , a monoclonal antibody that blocks terminal complement ... treating PNH patients with bone marrow transplantation and eculizumab are explored. Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders

    ... The recent availability of eculizumab as the first complement inhibitor renewed the interest for ... time, the growing information on biological changes during eculizumab treatment in PNH have improved our understanding of different steps ...

    Research Article last updated 10/02/2012 - 10:00am.